Bladder cancer begins in the cells lining the bladder wall, with blood in urine being the earliest warning sign. When detected early, the 5 year survival rate exceeds 90% — making prompt diagnosis the key to cure.
Globally, more than 650,000 new cases of bladder cancer are diagnosed annually, making it the 10th most common cancer worldwide. Many patients miss the best treatment window due to painless hematuria — but timely intervention can still open a window for curative outcomes, so seeking medical evaluation at the first sign of symptoms is crucial.
China sees over 90,000 new cases of bladder cancer each year, with incidence rising at 3.4% annually. At Fosun Health, this growing case volume has given our expert teams a depth of experience that ensures precision in every aspect of care — from early endoscopic detection and risk stratification to robotic assisted surgery, intravesical therapy, and systemic treatment.
Every bladder cancer program has surgery, BCG, and chemotherapy. Here is what makes ours different:
"I have non-muscle-invasive bladder cancer. Will I need endless surgeries? Or if it is muscle-invasive, must I lose my bladder? What if the cancer has spread?"
The challenge: Bladder cancer is not one disease—it spans a spectrum. Early-stage (NMIBC) tumors often recur after surgery, requiring repeated resections and bladder instillations. Muscle-invasive (MIBC) disease traditionally forces a choice between radical cystectomy and limited alternatives. Metastatic disease demands systemic therapy that must work quickly.
Our answer: A stage-matched, integrated platform that deploys chemotherapy and radiation precisely where they matter most:
For NMIBC (Non-Muscle-Invasive)：
- Transurethral Resection (TURBT): Removes the tumor through the natural passage—no external incision.
- Intravesical Chemotherapy: Postoperative instillation of mitomycin C, epirubicin, or gemcitabine directly into the bladder kills residual cancer cells and reduces recurrence. These drugs act locally with minimal systemic absorption.
- BCG Immunotherapy: For high-risk NMIBC, BCG triggers a localized immune attack against remaining tumor cells—dramatically lowering progression risk.
For MIBC (Muscle-Invasive) — The Bladder-Sparing "Trimodality"：
For patients who refuse or cannot undergo radical cystectomy, we offer maximal TURBT + concurrent chemoradiation + pelvic tumor hyperthermia. The chemotherapy (typically cisplatin or 5-FU) acts as a radiosensitizer—making cancer cells more vulnerable to radiation damage. External-beam radiation (IMRT/VMAT) is precisely sculpted to the bladder and pelvis, sparing the rectum and small bowel. Tumor hyperthermia at 40–43°C further amplifies the effect. Complete response rates rival surgery, with the bladder preserved and functional.
For Metastatic Disease：
- Systemic Platinum Chemotherapy: Gemcitabine + cisplatin (GC) or MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) remains the first-line backbone—shrinking tumors, relieving symptoms, and extending survival.
- Neoadjuvant Chemotherapy: For MIBC patients proceeding to radical cystectomy, cisplatin-based neoadjuvant chemotherapy before surgery improves cure rates by eliminating micrometastases early.
What this means for you: Whether your tumor is sitting on the surface or has invaded deeply, we have a chemotherapy and radiation strategy matched to your stage—aiming to preserve your bladder whenever possible, and to attack metastatic disease systemically when necessary.
"I have been passing blood for days. I am weak, dizzy, and my hemoglobin keeps dropping. The bladder irrigation isn't working. Can you stop this?"
The challenge: Hematuria is the signature symptom of bladder cancer. In advanced or recurrent disease, tumor surface bleeding can become torrential and continuous—filling the bladder with clots, blocking urine outflow, and causing severe anemia that leaves patients transfusion-dependent and too frail for cancer treatment.
Our answer: Superselective bladder artery embolization (BAE). Through a tiny groin puncture, a microcatheter navigates to the superior and inferior vesical arteries (branches of the internal iliac artery) that feed the tumor. Embolic agents are delivered precisely to seal the bleeding vessels. Hemorrhage stops immediately. The procedure takes 30–60 minutes. No abdominal incision. No general anesthesia.
For patients who continue to bleed diffusely from bladder mucosal disease, we also provide urgent cystoscopic clot evacuation and targeted fulguration to stabilize the patient.
What this means for you: When the bleeding won't stop and your strength is ebbing, our interventional team can seal the source in a single session—restoring your hemoglobin, your stability, and your ability to proceed with definitive cancer therapy.
"They say the tumor is blocking my ureter. My kidney is swollen with backed-up urine. I am in agony and my kidney function is failing. Can you save my kidney?"
The challenge: Bladder tumors near the ureteral orifices—or bulky tumors compressing the intramural ureter—cause malignant obstruction. Hydronephrosis builds pressure, destroying renal function from below. Without rapid decompression, the kidney suffers irreversible damage, and the patient faces a lifetime of dialysis before cancer treatment can even begin.
Our answer: Immediate urinary tract decompression and tumor control:
- Ureteral Stenting: A double-J (DJ) ureteral stent is placed cystoscopically or under fluoroscopy—bridging the blocked segment and allowing urine to flow from kidney to bladder again. Rapid relief of pain and preservation of renal function.
- Percutaneous Nephrostomy (PCN): When the ureter cannot be safely stented (severe distortion, tumor encasement), we place a drainage tube directly into the kidney through the back—immediately relieving pressure and protecting the organ.
- Interventional Tumor Shrinkage: Once the kidney is safe, superselective arterial infusion chemotherapy via the internal iliac artery delivers high-dose therapy directly to the tumor—shrinking the mass and potentially allowing removal of the stent later.
- Tumor Hyperthermia: For pelvic tumors undergoing concurrent chemoradiation, regional hyperthermia to 40–43°C acts as a force multiplier—making cancer cells more vulnerable to radiation and chemotherapy, accelerating tumor shrinkage to relieve ureteral compression faster.
What this means for you: When the kidney is drowning in backed-up urine, we open the floodgate—then attack the tumor that caused the dam. Your kidney survives. Your cancer treatment proceeds.
"My bladder cancer keeps coming back after BCG. Or I have metastatic disease and the platinum chemotherapy has stopped working. Is there truly nothing left?"
The challenge: Non-muscle-invasive bladder cancer that fails BCG (BCG-unresponsive) progresses to muscle invasion in many cases—and treatment options narrow dramatically. Metastatic urothelial carcinoma that resists platinum-based chemotherapy has historically carried a poor prognosis. Next-generation therapies exist, but in many regions they arrive late, if at all.
Our answer: In China, the next line comes sooner—and costs significantly less:
- PD-1/PD-L1 Immunotherapy: Tislelizumab, toripalimab, avelumab, and serplulimab are approved in China for advanced or metastatic urothelial carcinoma—delivering durable responses, particularly in patients with high PD-L1 expression, high tumor mutational burden, or MSI-H/dMMR.
- Antibody-Drug Conjugates (ADCs)：
Disitamab Vedotin (RC48)： A China-original HER2-targeting ADC with impressive response rates in HER2-overexpressing urothelial carcinoma—developed and manufactured domestically.
Enfortumab Vedotin (EV)： Targeting Nectin-4, approved for platinum-resistant disease and delivering substantial tumor shrinkage.
- FGFR-Targeted Therapy: For tumors with FGFR2 or FGFR3 alterations, erdafitinib provides a precision oral targeted option.
- Phase III Clinical Trial Fast-Track: When approved drugs fail, rapid access to trials of next-generation ADCs, novel FGFR inhibitors, dual immunotherapy combinations, and radioligand therapies—typically 3–5 years ahead of availability elsewhere.
Because these therapies are developed and manufactured within China's integrated ecosystem, comprehensive treatment costs are 30%–50% of what you would pay in Europe or the US—with zero compromise in quality.
Guided by NGS-based HER2, FGFR, PD-L1, and MSI profiling and physicians who have sequenced thousands of urothelial cancer cases through multiple lines.
What this means for you: BCG failure is not a dead end. Platinum resistance is not a terminal label. Your HER2, FGFR, or PD-L1 status maps directly to drugs that are available here, now—at a cost that makes sustained, multi-line treatment possible.
When standard therapies reach their limit, we provide rapid access to China's full portfolio of Phase III clinical trials—therapies typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific mutation. Every enrollment is ethics-approved with full medical supervision.
Our TCM program runs alongside your primary treatment as a "urinary function and vitality optimizer":
Toxicity Reduction: Herbal formulations help protect bladder mucosa, reduce chemotherapy-induced nausea and fatigue, ease radiation cystitis, and mitigate the burning and frequency from intravesical therapy.
Efficacy Enhancement: Selected preparations may improve tumor sensitivity to chemotherapy or radiation.
Acupuncture provides additional support for urinary urgency, pelvic discomfort, nausea, and treatment-related fatigue. The goal: protect your urinary comfort, reduce treatment burden, and keep you strong enough to complete every planned cycle.
Every bladder cancer case is reviewed by a panel comprising urologic oncology surgery, radiation oncology, medical oncology, interventional radiology, radiology, pathology, and clinical nutrition specialists. Bladder cancer decisions are uniquely complex: TURBT plus intravesical therapy versus radical cystectomy; bladder-sparing trimodality therapy versus immediate surgery; neobladder versus ileal conduit versus continent diversion; and sequencing of BCG, chemotherapy, immunotherapy, ADCs, and targeted agents through lines of resistance.
The MDT convenes within 48 hours of complete documentation. Your plan is a consensus decision optimized for your cancer stage, molecular profile, renal function, and your priorities.
Diagnosis:
Stage IIIA Muscle-Invasive Urothelial Carcinoma of the Bladder
Treatment Plan:
Maximal transurethral resection of bladder tumor (TURBT), followed by concurrent chemoradiotherapy, pelvic tumor hyperthermia, and adjuvant immunotherapy. The treatment strategy aimed to maximize tumor control while preserving bladder function and avoiding radical cystectomy. CyberKnife radiotherapy and pelvic hyperthermia were administered concurrently with chemotherapy. An immunotherapeutic agent available in China was continued for one year.
Outcome:
At the 2-year follow-up, PET/CT demonstrated marked tumor regression with the lesion becoming nearly undetectable. No evidence of metastasis or recurrence was observed, and renal function remained stable. The patient regained full independence in daily activities, was able to travel independently, and resumed gardening as a regular hobby.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
Upload your urinalysis, CT urography or MRI images, cystoscopy/TURBT pathology report, PET-CT, and NGS results (FGFR, HER2, MSI). Our multidisciplinary bladder cancer team will provide a personalized treatment plan—including bladder preservation assessment and neobladder candidacy—within 48 hours.
